Xeris Pharmaceuticals Inc. (XERS) saw its shares surge 7.84% in pre-market trading following the release of its fourth-quarter and full-year 2025 financial results.

The biopharmaceutical company reported quarterly earnings that significantly exceeded analyst expectations. Xeris posted Q4 EPS of $0.06, beating the consensus estimate of $0.04, and sales of $85.8 million, which surpassed estimates of $82.3 million. The strong performance was driven by robust growth across its key products, with Recorlev net revenue approximately doubling year-over-year, and both Gvoke and Keveyis showing solid growth due to increased patient demand and favorable pricing.

Furthermore, the company provided full-year 2026 revenue guidance in the range of $375 million to $390 million, which is above the consensus estimate of approximately $368 million. This positive outlook, coupled with the strong quarterly beat and a shift to net profitability, fueled significant investor optimism ahead of the market open.